Literature DB >> 29572267

Long-term visual outcome in patients treated by flow diversion for carotid-ophthalmic aneurysms.

Romain Touzé1,2, Valérie Touitou2,3, Eimad Shotar1,3, Joseph Gabrieli4, Mehdi Drir5, Bertrand Mathon3,6,3, Nader-Antoine Sourour1, Frédéric Clarençon1,3.   

Abstract

BACKGROUND: Flow-diverter stents (FDSs) are an upgrade in the treatment of intracranial aneurysms. However, complications concerning covered branches have been reported, especially the ophthalmic artery (OA). The purpose of our study was to evaluate the long-term ophthalmic complication rate of carotid-ophthalmic aneurysms (COA) without visual pathways compression, treated by a FDS covering the OA by performing an exhaustive ophthalmic examination.
MATERIAL AND METHODS: Retrospective analysis of a single-center database screening the patients treated from October 2009 to April 2015 for an intracranial aneurysm with a FDS. The patients treated for a non-compressive COA with coverage of the OA by the device were studied (n=30). Among these patients, 15 (50%) were excluded. The remaining 15 patients underwent a systematic and extensive ophthalmic examination at least 2 years after the stent placement by two ophthalmologists.
RESULTS: Fifteen patients with 16 COAs treated with a FDS were included. Mean follow-up was 4.1±2 years. Six patients (40%), presented ophthalmic complications, including three fugax amauroses (18.8%) and four significant visual field defects (25%). After comparing each eye's visual field's patients, we observed a significant difference between the eye on the FDS side compared with the contralateral eye, with a mean deviation of -1.58 dB versus -0.67 dB respectively (P=0.003). Visual acuity was preserved in all patients.
CONCLUSION: Patients treated by FDS for COA have a good long-term clinical ophthalmic outcome. However, extensive ophthalmic examination shows a high percentage of minor ophthalmic modifications. Interventional neuroradiologists should be aware of these possible complications when choosing to treat these aneurysms with FDS. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  aneurysm; blood flow; complication; flow diverter; orbit

Mesh:

Year:  2018        PMID: 29572267     DOI: 10.1136/neurintsurg-2017-013684

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  5 in total

Review 1.  Role of the ophthalmic artery in the endovascular treatment for intracranial vascular diseases.

Authors:  Kun Hou; Wei Wu; Ying Liu; Lai Qu; Baofeng Xu; Jinlu Yu
Journal:  Acta Neurol Belg       Date:  2021-01-05       Impact factor: 2.396

2.  Incomplete occlusion and visual symptoms of peri-ophthalmic aneurysm after treatment with a pipeline embolization device: a multi-center cohort study.

Authors:  Chao Xu; Pei Wu; Bowen Sun; Shancai Xu; Bin Luo; Xinjian Yang; Huaizhang Shi
Journal:  Acta Neurochir (Wien)       Date:  2022-05-13       Impact factor: 2.816

3.  Two patients of visual disturbance and optic perineuritis after placement of a flow diverter.

Authors:  Yuko Tanaka; Hiroki Nagatsuka; Yuma Miki; Yoshiaki Tetsuo; Hajime Yabuzaki; Sadayoshi Nakayama; Yoshikazu Matsuda; Tomoyuki Tsumoto; Tomoaki Terada
Journal:  Radiol Case Rep       Date:  2022-03-03

4.  Diagnostic Impact of Monitoring Visual Evoked Potentials to Prevent Visual Complications During Endovascular Treatment for Intracranial Aneurysm.

Authors:  Ichiro Nakagawa; HunSoo Park; Masashi Kotsugi; Shohei Yokoyama; Kouji Omoto; Kaoru Myochin; Yasuhiro Takeshima; Ryosuke Matsuda; Fumihiko Nishimura; Shuichi Yamada; Tsunenori Takatani; Hiroyuki Nakase
Journal:  Front Neurol       Date:  2022-02-23       Impact factor: 4.003

5.  Visual complications after coil embolization of internal carotid artery aneurysms at the ophthalmic segment.

Authors:  Shotaro Michishita; Toshihiro Ishibashi; Ichiro Yuki; Mitsuyoshi Urashima; Kostadin Karagiozov; Tomonobu Kodama; Issei Kan; Kengo Nishimura; Naoki Kato; Ayako Ikemura; Yuichi Murayama
Journal:  Interv Neuroradiol       Date:  2021-02-21       Impact factor: 1.764

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.